The recent surge in capital into boutique pharmaceutical companies, particularly those focusing on experimental therapies and challenging drug development programs, has fueled what some are calling "High Stakeholder https://rishiatit546424.onzeblog.com/40362935/premium-investor-pharma-a-risky-bet